<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2017.5953</article-id>
<article-id pub-id-type="publisher-id">or-38-05-2985</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Biochanin-A induces apoptosis and suppresses migration in FaDu human pharynx squamous carcinoma cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Cho</surname><given-names>In-A</given-names></name>
<xref rid="af1-or-38-05-2985" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>You</surname><given-names>Sang-Joun</given-names></name>
<xref rid="af2-or-38-05-2985" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Kang</surname><given-names>Kyeong-Rok</given-names></name>
<xref rid="af1-or-38-05-2985" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Kim</surname><given-names>Su-Gwan</given-names></name>
<xref rid="af1-or-38-05-2985" ref-type="aff">1</xref>
<xref rid="af6-or-38-05-2985" ref-type="aff">6</xref></contrib>
<contrib contrib-type="author"><name><surname>Oh</surname><given-names>Ji-Su</given-names></name>
<xref rid="af1-or-38-05-2985" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>You</surname><given-names>Jae-Seek</given-names></name>
<xref rid="af1-or-38-05-2985" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Lee</surname><given-names>Gyeong-Je</given-names></name>
<xref rid="af3-or-38-05-2985" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author"><name><surname>Seo</surname><given-names>Yo-Seob</given-names></name>
<xref rid="af4-or-38-05-2985" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Kim</surname><given-names>Do Kyung</given-names></name>
<xref rid="af5-or-38-05-2985" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chun Sung</given-names></name>
<xref rid="af5-or-38-05-2985" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sook-Young</given-names></name>
<xref rid="af6-or-38-05-2985" ref-type="aff">6</xref></contrib>
<contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jae-Sung</given-names></name>
<xref rid="af5-or-38-05-2985" ref-type="aff">5</xref>
<xref rid="c1-or-38-05-2985" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-or-38-05-2985"><label>1</label>Department of Oral and Maxillofacial Surgery, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<aff id="af2-or-38-05-2985"><label>2</label>Department of Periodontology, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<aff id="af3-or-38-05-2985"><label>3</label>Department of Prosthodontics, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<aff id="af4-or-38-05-2985"><label>4</label>Department of Oral and Maxillofacial Radiology, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<aff id="af5-or-38-05-2985"><label>5</label>Oral Biology Research Institute, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<aff id="af6-or-38-05-2985"><label>6</label>Regional Innovation Center for Dental Science and Engineering, School of Dentistry, Chosun University, Gwangju 61452, Republic of Korea</aff>
<author-notes>
<corresp id="c1-or-38-05-2985"><italic>Correspondence to</italic>: Professor Jae-Sung Kim, Department of Pre-Dentistry, School of Dentistry, Chosun University, 309 Philmun-daero, Dong-gu, Gwangju 61452, Republic of Korea, E-mail: <email>js_kim@chosun.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date>
<pub-date pub-type="epub"><day>13</day><month>09</month><year>2017</year></pub-date>
<volume>38</volume>
<issue>5</issue>
<fpage>2985</fpage>
<lpage>2992</lpage>
<history>
<date date-type="received"><day>21</day><month>03</month><year>2017</year></date>
<date date-type="accepted"><day>31</day><month>08</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2017, Spandidos Publications</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<abstract>
<p>The aim of the present study was to investigate biochanin-A-induced anticancer effects and their cellular signaling pathway in FaDu pharyngeal squamous carcinoma cells. Biochanin-A induced cell death through increased cytotoxicity of FaDu cells in a dose- and time-dependent manner. The number of cells with nucleus condensation and the apoptotic population were increased in the FaDu cells stimulated with biochanin-A for 24 h. Furthermore, extrinsic apoptotic factors such as FasL and their downstream target caspase-8 were increased and activated in the FaDu cells treated with biochanin-A in a dose-dependent manner. Moreover, biochanin-A decreased the expression of intrinsic anti-apoptotic factors such as Bcl-2 and Bcl-xL, and increased the level and activation of intrinsic apoptotic factors such as Bad and caspase-9. Finally, biochanin-A induced the activation of caspase-3 and Poly(ADP ribose) polymerase (PARP) in FaDu cells. Our results suggest that biochanin-A-induced apoptosis was mediated by death receptor mediated-extrinsic and mitochondria-dependent intrinsic apoptotic signaling pathways. Biochanin-A also inhibited wound healing migration and proliferation of FaDu cells via the downregulation and inactivation of matrix metalloproteinase-2 and &#x2212;9 that are mediated by the suppression of p38, mitogen activated protein kinase (MAPK), NF-&#x03BA;B and Akt cellular signaling pathways. Therefore, these data suggest that the biochanin-A may act as a potential chemotherapeutic compound to treat head and neck cancer.</p>
</abstract>
<kwd-group>
<kwd>biochanin-A</kwd>
<kwd>pharynx squamous carcinoma</kwd>
<kwd>apoptosis</kwd>
<kwd>migration</kwd>
<kwd>chemotherapeutic agent</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer with over 640,000 cases diagnosed annually and high mortality worldwide (<xref rid="b1-or-38-05-2985" ref-type="bibr">1</xref>). Lifestyles such as smoking, alcohol consumption, and betel nut chewing are primary etiological factors of HNSCC and are linked to the increased prevalence of HNSCC worldwide (<xref rid="b2-or-38-05-2985" ref-type="bibr">2</xref>). Although clinical interventions such as surgery, radiotherapy, chemotherapy, and chemo-radiotherapy have rapidly advanced, 5-year survival and morbidity rates of patients with HNSCC have not improved significantly in the last 30 years (<xref rid="b2-or-38-05-2985" ref-type="bibr">2</xref>,<xref rid="b3-or-38-05-2985" ref-type="bibr">3</xref>). Furthermore, despite the advancement of diagnostic techniques and therapeutics, clinical interventions frequently result in irreversible loss of function and disfigurement (<xref rid="b4-or-38-05-2985" ref-type="bibr">4</xref>). Therefore, there is an urgent need to develop chemotherapeutic agents that effectively treat the cancer with fewer adverse effects.</p>
<p>Recently, natural compounds purified from herbal plants used traditionally in folk and oriental medicine have received considerable interest as a potential preventive or clinical drugs due to their various pharmacological effects combined with potential biological safety (<xref rid="b5-or-38-05-2985" ref-type="bibr">5</xref>). Many recent studies have tested the anticancer effects of natural compounds to develop chemotherapeutic agents with fewer side-effects. Due to these studies, several natural compounds with effective anticancer effects and strong safety data have been used as clinical chemotherapeutic agents for cancer patients, after approval by the United States Food and Drug Administration (<xref rid="b5-or-38-05-2985" ref-type="bibr">5</xref>).</p>
<p>Apoptosis is defined as programmed cell death characterized by morphological shrinkage (<xref rid="b6-or-38-05-2985" ref-type="bibr">6</xref>), nucleus condensation (<xref rid="b7-or-38-05-2985" ref-type="bibr">7</xref>) and DNA degradation (<xref rid="b8-or-38-05-2985" ref-type="bibr">8</xref>). Cancer cell-specific apoptosis is one of current strategies for developing chemotherapeutic agents from natural compounds (<xref rid="b9-or-38-05-2985" ref-type="bibr">9</xref>).</p>
<p>Biochanin-A (5,7-dihydroxy-4-methoxy-isoflavone) is a phytoestrogen, which is a natural estrogen analogue, derived from edible and herbal plants such as peanuts, alfalfa sprouts, soy and red clover (<xref rid="b10-or-38-05-2985" ref-type="bibr">10</xref>). Recent studies have reported that biochanin-A alleviates climacteric vasomotor symptoms and reduces low-density lipoprotein levels in menopausal women (<xref rid="b11-or-38-05-2985" ref-type="bibr">11</xref>). Furthermore, biochanin-A has been reported to possess various pharmacological effects including antioxidant activity (<xref rid="b12-or-38-05-2985" ref-type="bibr">12</xref>), anti-inflammation (<xref rid="b13-or-38-05-2985" ref-type="bibr">13</xref>), neuroprotection (<xref rid="b14-or-38-05-2985" ref-type="bibr">14</xref>) and the prevention of articular cartilage degeneration (<xref rid="b10-or-38-05-2985" ref-type="bibr">10</xref>). Biochanin-A has also been reported to show anticancer activity such as increased radiotoxicity in colon cancer (<xref rid="b15-or-38-05-2985" ref-type="bibr">15</xref>), the increased survival in pancreatic cancer, and induction of apoptosis in prostate cancer (<xref rid="b16-or-38-05-2985" ref-type="bibr">16</xref>) and hepatoma (<xref rid="b17-or-38-05-2985" ref-type="bibr">17</xref>).</p>
<p>Therefore, the aim of the present study was to determine whether biochanin-A has the potential to function as a chemotherapeutic agent to treat HNSCC. We evaluated the potential apoptotic effects of biochanin-A on HNSCC and elucidated the induced apoptotic signaling pathway.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell culture</title>
<p>FaDu cells originating from human pharynx squamous carcinoma were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured by following the instruction provided by ATCC. Briefly, FaDu cells were maintained in minimum essential medium (MEM; Gibco, Grand Island, NY, USA) containing 10&#x0025; fetal bovine serum (FBS; Gibco, Grand Island, NY, USA), 100 &#x00B5;g/ml streptomycin and 100 Unit/ml penicillin (Gibco) in a humidified, 5&#x0025; CO<sub>2</sub> and 37&#x00B0;C incubator.</p>
</sec>
<sec>
<title>Cell cytotoxicity assay</title>
<p>To determine the cytotoxicity of biochanin-A in FaDu cells, the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed as previously described (<xref rid="b2-or-38-05-2985" ref-type="bibr">2</xref>). Briefly, FaDu cells were cultured at a density of 0.2&#x00D7;0<sup>5</sup> cells/ml in 96-well plates and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25, 50 and 100 &#x00B5;M biochanin-A (Santa Cruz Biotechnology, Dallas, TX, USA) for 24 and 48 h. Thereafter, 200 &#x00B5;l of 5 mg/ml MTT (Sigma-Aldrich, St. Louis, MO, USA) was added into cultured FaDu cells and incubated for another 4 h. Sequentially, supernatant was removed, and MTT crystals were dissolved in 200 &#x00B5;l/well dimethyl sulfoxide (DMSO; Sigma-Aldrich). Finally, optical density was measured at 570 nm by a spectrophotometer (Epoch; BioTek Instruments, Inc., Winooski, VT, USA).</p>
</sec>
<sec>
<title>Live and dead cell assay</title>
<p>To visualize the live and dead FaDu cells following treatment with biochanin-A, the cell live and dead assay was performed with green calcein AM and ethidium homodimer-1 as previously described (<xref rid="b4-or-38-05-2985" ref-type="bibr">4</xref>). Briefly, FaDu cells were cultured at a density of 0.2&#x00D7;10<sup>5</sup> cells/ml in an 8-well chamber slide (Electron Microscopy Sciences, Hatfield, PA, USA) and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Thereafter, to visualize either live or dead FaDu cells, live and dead cell assay was performed by live and dead cell assay kit (Thermo Fisher Scientific, Rockford, IL, USA), which is composed of green calcein AM to stain the live cells with green fluorescence and ethidium homodimer-1 to stain the dead cells with red fluorescence, following the instructions provided by the manufacturer. Cells were imaged using fluorescence microscopy (Eclipse TE2000; Nikon Instruments, Inc., Melville, NY, USA).</p>
</sec>
<sec>
<title>DAPI staining</title>
<p>To determine the nucleus condensation in FaDu cells treated with biochanin-A, DAPI (4&#x2032;,6-diamidino-2-phenylindole) staining was performed by the protocol previously described (<xref rid="b18-or-38-05-2985" ref-type="bibr">18</xref>). Briefly, FaDu cells were cultured at a density of 0.2&#x00D7;10<sup>5</sup> cells/ml in an 8-well chamber slide (Electron Microscopy Sciences) and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Thereafter, FaDu cells were fixed with 4&#x0025; paraformaldehyde after washing with phosphate-buffered solution (PBS) and stained with 1 mg/ml DAPI for 20 min. The nucleus of FaDu cells were imaged using fluorescence microscopy (Eclipse TE2000; Nikon Instruments).</p>
</sec>
<sec>
<title>Flow cytometric analysis</title>
<p>Flow cytometric analysis (FACS) was performed to determine the extent of apoptosis and necrosis using Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI), respectively. The FaDu cells were cultured at a density of 1&#x00D7;10<sup>5</sup> cells/ml and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Thereafter, FaDu cells were washed twice in PBS and re-suspended in a binding buffer (BD Biosciences, San Diego, CA, USA). Annexin V-FITC and PI (BD Biosciences) were added to the cells and incubated in the dark for 15 min. The cells were analyzed using a fluorescence-activated cell sorting Calibur flow cytometer (Becton-Dickinson, San Jose, CA, USA). Data analysis was performed using standard CellQuest software (Becton-Dickinson) and WinMDI version 2.9 software (The Scripps Research Institute, San Diego, CA, USA).</p>
</sec>
<sec>
<title>Immunoblotting</title>
<p>The FaDu cells were cultured at a density of 1&#x00D7;10<sup>5</sup> cells/ml and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Thereafter, FaDu cells were harvested, lysed using cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) containing protease inhibitor (Sigma-Aldrich) and phosphatase inhibitor cocktails (Sigma-Aldrich) according to the manufacturers protocol. Total protein concentrations of cell lysates were determined by bicinchoninic acid (BCA) protein assays (Pierce, Rockford, IL, USA). In addition, conditioned media were harvested to detect the proteins secreted from FaDu cells. Equal amounts of protein and conditioned media were mixed with 5X loading buffer, boiled at 90&#x00B0;C for 10 min, separated using sodium dodecyl sulfate polyacrylamide gene electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (BD Biosciences). After blocking with 5&#x0025; bovine serum albumin (BSA; Sigma-Aldrich) in TBS-T (Tris-buffered saline with 0.1&#x0025; Tween-20 (Sigma-Aldrich) at room temperature for 1 h, membranes were reacted with TBS-T containing 5&#x0025; BSA and primary antibodies of the corresponding proteins at 4&#x00B0;C for 12 h and then incubated with horseradish peroxidase-conjugated secondary antibody. The following antibodies were used: antibodies against FasL, caspases (&#x2212;3, &#x2212;7, &#x2212;8 and &#x2212;9), Bcl-2, Bcl-xL, Bad, Poly(ADP ribose) polymerase (PARP), phospho-NF-&#x03BA;B and total NF-&#x03BA;B were purchased from Cell Signaling Technology. &#x03B2;-actin, phospho-ERK, total ERK, phospho-p38, total p-38, phospho-Akt, total Akt, matrix metalloproteinase (MMP)-2 and MMP-9 were purchased from Santa Cruz Biotechnology. The immunoreactive bands were visualized using the ECL system (Amersham Biosciences, Piscataway, NJ, USA) and were exposed on radiographic film.</p>
</sec>
<sec>
<title>In vitro migration assay</title>
<p>To perform the migration assay, FaDu cells were cultured onto 2&#x00D7;0.22 cm<sup>2</sup> culture inserts (Ibidi, Regensburg, Germany) at a density of 1&#x00D7;10<sup>4</sup> cells/well. Wounds were introduced by removing the culture inserts after 24 h of incubation. Thereafter, cultured FaDu cells were treated with 25 &#x00B5;M biochanin-A for 48 and 72 h. Wound widths were imaged using an inverted microscope (Eclipse TE2000; Nikon Instruments).</p>
</sec>
<sec>
<title>Colony formation assay</title>
<p>A colony formation assay was performed according to the previously described protocol (<xref rid="b19-or-38-05-2985" ref-type="bibr">19</xref>). Briefly, FaDu cells were cultured at a density of 200 cells/well in a 6-well culture plate and allowed to attach to the well overnight. After incubation, cultured FaDu cells were treated with 25 and 50 &#x00B5;M biochanin-A for 24 h and were then incubated in culture medium without biochanin-A for 5 days. Thereafter, the medium was removed and the cells were washed with PBS and fixed with 4&#x0025; paraformaldehyde for 10 min at 4&#x00B0;C. Sequentially, the colonies were stained with 2&#x0025; crystal violet for 10 min. Finally, the colonies were washed with PBS and dried at room temperature, before being imaged by a digital camera (Nikon Instruments).</p>
</sec>
<sec>
<title>Gelatin zymography</title>
<p>Gelatin zymography was performed to assess the activity of matrix metalloproteinases (MMPs) secreted from FaDu cells treated with biochanin-A. An equal volume of conditioned media was mixed with non-reducing sample buffer [4&#x0025; SDS, 0.15 M Tris (pH 6.8) and 20&#x0025; (v/v) glycerol containing 0.05&#x0025; (w/v) bromophenol blue] and resolved on a 10&#x0025; polyacrylamide gel containing copolymerized 0.2&#x0025; (1 mg/ml) swine skin gelatin. After electrophoresis of the conditioned media samples, gels were washed with cold PBS containing 2.5&#x0025; (v/v) Triton X-100 for 30 min and washed twice with cold PBS for 15 min. After washing, gels were incubated in the zymogram renaturing buffer [50 mM Tris-HCl (pH 7.6), 10 mM CaCl<sub>2</sub>, 50 mM NaCl and 0.05&#x0025; Brij-35) at 37&#x00B0;C for 72 h. After renaturation of MMPs, gels were stained with 0.1&#x0025; Coomassie brilliant blue R250. The gelatinolytic activity was revealed as a clear band on a background of uniform light blue staining.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Data are reported as the mean &#x00B1; SD of three individual experiments performed. Statistical analysis was carried out using the Student&#x0027;s t-test and a P-value &#x003C;0.05 was considered to indicate a statistically significant result.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Biochanin-A induces death of FaDu cells via increased cytotoxicity</title>
<p>To measure the viability of FaDu cells treated with 25, 50 and 100 &#x00B5;M biochanin-A for 24 and 48 h, MTT assays were performed. As shown in <xref rid="f1-or-38-05-2985" ref-type="fig">Fig. 1A</xref>, relative viabilities of FaDu cells treated with 25, 50 and 100 &#x00B5;M biochanin-A for 24 h are 84&#x00B1;7.2, 63&#x00B1;5.15 and 48&#x00B1;2.4&#x0025;, respectively, compared to non-treated control (102&#x00B1;5.1&#x0025;). Furthermore, relative viabilities of FaDu cells treated with the same concentrations of biochanin-A for 48 h are 47&#x00B1;5.3, 32&#x00B1;1.6 and 11&#x00B1;5.5&#x0025;, respectively. Live and dead cell assays were performed to visualize the live and dead cells after treatment with 25 and 50 &#x00B5;M biochanin-A for 24 h. In the non-treated control, as shown in <xref rid="f1-or-38-05-2985" ref-type="fig">Fig. 1B</xref>, almost all cells are stained fluorescent green by membrane permeable calcein AM, which is cleaved by cytosolic esterase in living cells. In contrast, the number of dead cells stained fluorescent red by ethidium homodimer-1 increases with biochanin-A treatment in a dose-dependent manner. The relative rate of live FaDu cells after treatment with 25 and 50 &#x00B5;M biochanin-A were measured as 78.5&#x00B1;4.7 and 63.5&#x00B1;9&#x0025;, respectively. These results consistently demonstrate that biochanin-A suppresses the viability of FaDu cells through an increase in cell cytotoxicity, in a dose- and time-dependent manner.</p>
</sec>
<sec>
<title>Biochanin-A induced FaDu cell death is mediated by apoptosis</title>
<p>Nucleus condensation is a typical phenomenon of apoptosis (<xref rid="b7-or-38-05-2985" ref-type="bibr">7</xref>). Therefore, DAPI staining was performed to observe the nucleus morphology of FaDu cells treated with biochanin-A. As shown in <xref rid="f2-or-38-05-2985" ref-type="fig">Fig. 2A</xref>, the relative rate of FaDu cells without condensed nucleus is ~85.9&#x00B1;4.7 and 66.0&#x00B1;5.9&#x0025; at 25 and 50 &#x00B5;M biochanin-A compared with non-treated control, respectively. These data show that biochanin-A increased the number of FaDu cells with condensed nuclei in a dose-dependent manner. Therefore, to verify the biochanin-A-induced apoptosis of FaDu cells, FACS analysis was performed using Annexin V-FITC and PI. As shown in <xref rid="f2-or-38-05-2985" ref-type="fig">Fig. 2B</xref>, the apoptotic population of FaDu cells treated with 50 &#x00B5;M biochanin-A increases ~4.2-fold compared with than non-treated control. Taken together, these data consistently indicate that biochanin-A-induced FaDu cell death is mediated by apoptosis.</p>
</sec>
<sec>
<title>Biochanin-A induces the apoptosis of FaDu cell through extrinsic and intrinsic apoptotic pathways</title>
<p>Next, to verify biochanin-A-induced apoptosis in FaDu cells, the alteration in expression of pro- and anti-apoptotic factors were observed by western blot analysis. As shown in <xref rid="f3-or-38-05-2985" ref-type="fig">Fig. 3</xref>, the expression of death ligand FasL (48 kDa) increases in FaDu cells treated with 25 and 50 &#x00B5;M biochanin-A in a dose-dependent manner. Sequentially, the expression of full length caspase-8 (57 kDa), which is a down-stream target molecule of FasL and is part of the death receptor mediated extrinsic apoptotic signaling pathway, gradually decreased in the FaDu cells treated with biochanin-A. In contrast, the expression of cleaved caspase-8 (43 kDa) increased due to the cleavage of full length caspase-8 by FasL in the FaDu cells treated with biochanin-A. Furthermore, the expression of cleaved caspase-3 increased due to the cleavage of full length caspase-3 (35 kDa) by the cleaved caspase-8. Sequentially, the expression of cleaved PARP (89 kDa; full length PARP: 116 kDa) increased by cleaved caspase-3 and then induced apoptosis. Therefore, these data indicate that the biochanin-A induces cells death through the FasL-caspase-8-caspase-3-PARP axis mediated extrinsic apoptosis signaling pathway in FaDu cells.</p>
<p>Furthermore, the expressions of Bcl-2 (26 kDa) and Bcl-xL (26 kDa), anti-apoptotic factors associated with the mitochondria-dependent apoptotic signaling pathway, decreased in the FaDu cells treated with 25 and 50 &#x00B5;M biochanin-A in a dose-dependent manner. Whereas, biochanin-A increased the expression of Bad (20 kDa) and cleaved caspase-9 (35 kDa; full length caspase-9: 47 kDa), pro-apoptotic factors associated with the mitochondria-dependent apoptotic signaling pathway. The cleaved caspase-9 increased the amount of cleaved caspase-3 and cleaved PARP and then induced the apoptosis of FaDu cells treated with biochanin-A. Therefore, these data indicate that biochanin-A induces cell death via the mitochondria-dependent intrinsic apoptosis signaling pathway in FaDu cells.</p>
</sec>
<sec>
<title>Biochanin-A suppresses the migration and proliferation of FaDu cells through the downregulation and inactivation of MMP-2 and &#x2212;9</title>
<p>FaDu cells were treated with 25 &#x00B5;M biochanin-A for 48 and 72 h to verify whether biochanin-A can suppress the migration and invasion. As shown in <xref rid="f4-or-38-05-2985" ref-type="fig">Fig. 4A</xref>, biochanin-A effectively suppressed migration compared with non-treated control. In addition, to verify whether biochanin-A suppress the proliferation of FaDu cells, a colony formation assay was performed as shown in <xref rid="f4-or-38-05-2985" ref-type="fig">Fig. 4B</xref>. The number of colonies in the untreated control was 168&#x00B1;42. In contrast, the number of colonies was 55&#x00B1;6.6 in the FaDu cells treated with 25 &#x00B5;M biochanin-A for 5 days. These data indicate that biochanin-A effectively suppressed the migration and proliferation of FaDu cells. In order to verify the expression alteration of implicating factors associated with the migration and proliferation of cancer cells, western blot analysis and gelatin zymography were performed as shown as <xref rid="f4-or-38-05-2985" ref-type="fig">Fig. 4C and D</xref>, respectively. The expressions of MMP-2 and MMP-9 gradually decreased in the FaDu cells treated with 25 and 50 &#x00B5;M biochanin-A in a dose-dependent manner. Clear bands formed on the gelatin zymogram gels by active MMPs gradually decreased in the FaDu cells treated with 25 and 50 &#x00B5;M biochanin-A in a dose-dependent manner. These data consistently indicate that biochanin-A suppresses the migration and invasion of FaDu cells through the downregulation expression and activation of MMPs. Taken together, these data suggest that the biochanin-A may act as a potential anti-metastatic reagent in HNSCC.</p>
<p>To verify the cellular signaling associated with migration and proliferation of FaDu cells, alterations in ERK1/2, p38 and NF-&#x03BA;B expression were observed by immunoblotting in FaDu cells treated with 50 &#x00B5;M biochanin-A for 15, 30 and 60 min as shown in <xref rid="f5-or-38-05-2985" ref-type="fig">Fig. 5</xref>. Biochanin-A did not induce the phosphorylation of ERK1/2 in FaDu cells at the defined treatment time, whereas, the phosphorylation of p38 and NF-&#x03BA;B decreased in the FaDu cells treated with biochanin-A in a time-dependent manner compared with non-treated control. Furthermore, the phosphorylation of Akt, which is closely associated with cellular signaling of cell proliferation, significantly decreased in FaDu cells treated with biochanin-A, in a time-dependent manner compared with non-treated control. Therefore, these data suggest that biochanin-A induced suppression of migration and proliferation is associated with the alteration of p38 MAPK, NF-&#x03BA;B and PI3K/Akt cellular signaling pathways in FaDu cells.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Oral cancer is the most common type of head and neck cancer and head and neck squamous cell carcinomas worldwide (<xref rid="b20-or-38-05-2985" ref-type="bibr">20</xref>). Despite therapeutic and technological advances, the 5-year survival rate of oral cancer has not increased (<xref rid="b21-or-38-05-2985" ref-type="bibr">21</xref>). Furthermore, the clinical interventions for patients with oral cancer have multiple serious side-effects such as the loss of function of speech, breathing, mastication and swallowing (<xref rid="b22-or-38-05-2985" ref-type="bibr">22</xref>). Therefore, to reduce the side-effects caused by clinical interventions to treat oral cancer, the development of chemotherapy using natural compounds that possess anticancer properties and excellent biological safety is critical.</p>
<p>Phytoestrogens are plant-derived compounds that are structurally and physiologically similar to estrogen. Recent studies have reported that the phytoestrogens such as coumestrol, kaempferol and genistein induce apoptosis in various cancers including breast, prostate and hepatocellular carcinoma (<xref rid="b23-or-38-05-2985" ref-type="bibr">23</xref>&#x2013;<xref rid="b25-or-38-05-2985" ref-type="bibr">25</xref>).</p>
<p>Biochanin-A is a phytoestrogen derived from red clover and used as a folk medicine worldwide. In the present study, we demonstrated that biochanin-A induced anticancer activities including the suppression of cellular proliferation and migration, and the increase in apoptosis through the induction of caspase activation in FaDu head and neck squamous cell carcinoma.</p>
<p>In our previous study, we reported that biochanin-A did not affect the viability of primary chondrocytes isolated from the articular cartilage of rats for 21 days (<xref rid="b10-or-38-05-2985" ref-type="bibr">10</xref>). However, the present study showed that biochanin-A increased cell death through the increase of cytotoxicity in FaDu cells, as shown in <xref rid="f1-or-38-05-2985" ref-type="fig">Fig. 1</xref>. Furthermore, recent studies have reported that biochanin-A increased the cytotoxicity of pancreatic (<xref rid="b26-or-38-05-2985" ref-type="bibr">26</xref>) and prostate cancer (<xref rid="b16-or-38-05-2985" ref-type="bibr">16</xref>). Therefore, these studies suggest that biochanin-A is a phytoestrogen that induce specific cancer cell death.</p>
<p>DNA fragmentation caused by nucleus condensation is a typical phenomenon of apoptosis, which is a programmed cell death. As shown in <xref rid="f2-or-38-05-2985" ref-type="fig">Fig. 2A</xref>, the number of FaDu cells with condensed nucleus was increased by biochanin-A in a dose-dependent manner. Therefore, these data indicate that biochanin-A-induced FaDu cell death may involve apoptosis. In order to verify this, FACS analysis using Annexin V and PI staining was performed, as shown in <xref rid="f2-or-38-05-2985" ref-type="fig">Fig. 2B</xref>. At the early stage of apoptosis, membrane phosphatidylserine is translocated to the cell surface from the inner plasma membrane. Therefore, Annexin V, which is a Ca<sup>2&#x002B;</sup>-dependent phospholipid-binding protein with binding activity to phosphatidylserine, was used as a marker to detecting the early stage of apoptosis (<xref rid="b21-or-38-05-2985" ref-type="bibr">21</xref>). Furthermore, translocated membrane phosphatidylserine precedes the loss of membrane integration. Subsequently, PI without membrane permeability binds to DNA by intercalating between the bases through the membranes of dead and damaged cells in the late stage of apoptosis (<xref rid="b21-or-38-05-2985" ref-type="bibr">21</xref>). In this study, the results of FACS analysis showed that the biochanin-A increased the apoptotic population of FaDu cells in both early and late stage compared with non-treated control. Taken together, these data consistently indicate that biochanin-A induces apoptosis in FaDu cells.</p>
<p>Apoptosis is generally divided into the death receptor mediated extrinsic pathway and mitochondrial-dependent intrinsic pathway (<xref rid="b27-or-38-05-2985" ref-type="bibr">27</xref>,<xref rid="b28-or-38-05-2985" ref-type="bibr">28</xref>). The death receptor mediated extrinsic pathways are triggered by death ligands such as FasL and TNF-related apoptosis-inducing ligand (TRAIL), and are sequentially mediated by the activation of caspase-8, caspase-3, and PARP to induce DNA fragmentation (<xref rid="b27-or-38-05-2985" ref-type="bibr">27</xref>,<xref rid="b28-or-38-05-2985" ref-type="bibr">28</xref>). However, the mitochondria-dependent intrinsic pathway associated with apoptosis is triggered by growth hormone withdrawal, DNA damage by UV- or &#x03B3;-radiation, chemotherapeutic drugs, and the activation of caspase-8 associated death receptor mediated extrinsic apoptosis through the upregulation or activation of pro-apoptotic factors such as Bad, Bid, Bax and caspase-9 and the downregulation of anti-apoptotic factors such as Bcl-2 and Bcl-xL (<xref rid="b27-or-38-05-2985" ref-type="bibr">27</xref>,<xref rid="b28-or-38-05-2985" ref-type="bibr">28</xref>). Finally, activated caspase-9 induces the activation of caspase-3 and PARP to induce DNA fragmentation (<xref rid="b27-or-38-05-2985" ref-type="bibr">27</xref>,<xref rid="b28-or-38-05-2985" ref-type="bibr">28</xref>). In the present study, biochanin-A increased the expression of FasL and induced the activation of its downstream pro-apoptotic factor caspase-8 as shown in <xref rid="f3-or-38-05-2985" ref-type="fig">Fig. 3</xref>. Furthermore, the expression of anti-apoptotic factors such as Bcl-2 and Bcl-xL dose-dependently decreased in the FaDu cells treated with biochanin-A. Whereas, biochanin-A increased the expression of Bad and activated caspase-9 in FaDu cells. Finally, both activated caspase-8 and caspase-9 increased the activation of caspase-3 and PARP to induce the apoptosis of FaDu cells treated with biochanin-A. Therefore, these data indicate that biochanin-A-induced FaDu cell death is mediated by both death receptor mediated extrinsic and mitochondria dependent intrinsic apoptosis pathways.</p>
<p>Next, in the present study, we demonstrated that the migration and proliferation of FaDu cells were significantly decelerated by biochanin-A as shown in <xref rid="f4-or-38-05-2985" ref-type="fig">Fig. 4A and B</xref>. Cancer cells metastasize to other tissues through bloodstream and lymphatic system in the terminal stage of cancer (<xref rid="b29-or-38-05-2985" ref-type="bibr">29</xref>). Hence, the deceleration of cancer cell growth and the suppression of metastasis are crucial aims of clinical treatment for metastatic cancer (<xref rid="b30-or-38-05-2985" ref-type="bibr">30</xref>). Furthermore, the expressional upregulation and activation of matrix metalloproteinase such as MMP-2 and MMP-9 are crucial factors associated with the migration and proliferation of cancer cells (<xref rid="b29-or-38-05-2985" ref-type="bibr">29</xref>,<xref rid="b31-or-38-05-2985" ref-type="bibr">31</xref>). We demonstrated that the expression and activation of MMP-2 and MMP-9 significantly decreased in the FaDu cells treated with biochanin-A, as shown in <xref rid="f4-or-38-05-2985" ref-type="fig">Fig. 4C and D</xref>. Taken together, biochanin-A decelerates the migration and proliferation of FaDu cells through the expression downregulation and inactivation of MMP-2 and MMP-9.</p>
<p>In the present study, biochanin-A suppressed the phosphorylation of p38 MAPK and NF-&#x03BA;B in FaDu cells as shown in <xref rid="f5-or-38-05-2985" ref-type="fig">Fig. 5</xref>. As well as this study, Kole <italic>et al</italic> (<xref rid="b32-or-38-05-2985" ref-type="bibr">32</xref>), reported that biochanin-A-induced anti-proliferation through the inhibition of p38 MAPK and the blocking of NF-&#x03BA;B nuclear translocation. Recent studies have also reported that the expression of MMP-2 and MMP-9, associated with cell growth, proliferation and migration, are closely regulated by MAPK cellular signaling in various cancer cells including colon cancer (<xref rid="b33-or-38-05-2985" ref-type="bibr">33</xref>) and osteosarcoma (<xref rid="b34-or-38-05-2985" ref-type="bibr">34</xref>). Furthermore, Bindhu <italic>et al</italic> (<xref rid="b35-or-38-05-2985" ref-type="bibr">35</xref>) and Qin <italic>et al</italic> (<xref rid="b36-or-38-05-2985" ref-type="bibr">36</xref>) reported that the activation of MMP-2 is closely regulated by NF-&#x03BA;B cellular signaling in oral squamous cell carcinoma and breast cancer. These consistently indicate that biochanin-A-induced anti-proliferation and anti-migration are mediated by the expressional downregulation and inactivation of MMP-2 and MMP-9 through the suppression of p38 MAPK and NF-&#x03BA;B cellular signaling pathways in FaDu cells. In addition, PI3K/Akt signaling is closely associated with cell proliferation, survival, growth and metastasis (<xref rid="b37-or-38-05-2985" ref-type="bibr">37</xref>,<xref rid="b38-or-38-05-2985" ref-type="bibr">38</xref>). Recent studies have reported that the suppression of PI3K/Akt signaling enhances cytotoxicity through the inhibition of the mTOR signaling pathway in various cancers such as breast and colorectal cancer (<xref rid="b39-or-38-05-2985" ref-type="bibr">39</xref>&#x2013;<xref rid="b41-or-38-05-2985" ref-type="bibr">41</xref>). In the present study, we demonstrated that biochanin-A suppressed the phosphorylation of Akt in FaDu cells. Taken together, these studies indicate that biochanin-A-induced anticancer activities including apoptosis, anti-proliferation, and anti-migration may be mediated by the suppression of PI3K/Akt cellular signaling pathway in FaDu cells.</p>
<p>In conclusion, we demonstrated that biochanin-A-induced anti-apoptotic effects such as death receptor mediated extrinsic and mitochondria-dependent intrinsic apoptosis, anti-metastasis and anti-proliferation in FaDu cells. These findings suggest that biochanin-A may be a promising natural chemotherapy candidate for HNSCC treatment.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by a research fund from the Chosun University Dental Hospital, 2016.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-or-38-05-2985"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacko</surname><given-names>M</given-names></name><name><surname>Braakhuis</surname><given-names>BJ</given-names></name><name><surname>Sturgis</surname><given-names>EM</given-names></name><name><surname>Boedeker</surname><given-names>CC</given-names></name><name><surname>Su&#x00E1;rez</surname><given-names>C</given-names></name><name><surname>Rinaldo</surname><given-names>A</given-names></name><name><surname>Ferlito</surname><given-names>A</given-names></name><name><surname>Takes</surname><given-names>RP</given-names></name></person-group><article-title>Genetic susceptibility to head and neck squamous cell carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>89</volume><fpage>38</fpage><lpage>48</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.09.034</pub-id><pub-id pub-id-type="pmid">24725688</pub-id></element-citation></ref>
<ref id="b2-or-38-05-2985"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Cho</surname><given-names>IA</given-names></name><name><surname>Oh</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Moon</surname><given-names>SM</given-names></name><name><surname>Cho</surname><given-names>SS</given-names></name><name><surname>Yoon</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated TRAIL expression in head and neck squamous carcinoma FaDu cells</article-title><source>Food Chem Toxicol</source><volume>77</volume><fpage>34</fpage><lpage>43</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.fct.2014.12.013</pub-id><pub-id pub-id-type="pmid">25572524</pub-id><pub-id pub-id-type="pmcid">4522946</pub-id></element-citation></ref>
<ref id="b3-or-38-05-2985"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigneswaran</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Annapragada</surname><given-names>A</given-names></name><name><surname>Zacharias</surname><given-names>W</given-names></name></person-group><article-title>Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC)</article-title><source>Exp Mol Pathol</source><volume>90</volume><fpage>215</fpage><lpage>225</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.yexmp.2010.11.011</pub-id><pub-id pub-id-type="pmid">21236253</pub-id><pub-id pub-id-type="pmcid">3057178</pub-id></element-citation></ref>
<ref id="b4-or-38-05-2985"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Oh</surname><given-names>D</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>JJ</given-names></name><name><surname>Kang</surname><given-names>KR</given-names></name><name><surname>Cho</surname><given-names>IA</given-names></name><name><surname>Moon</surname><given-names>SM</given-names></name><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>You</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Berberine induces FasL-related apoptosis through p38 activation in KB human oral cancer cells</article-title><source>Oncol Rep</source><volume>33</volume><fpage>1775</fpage><lpage>1782</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/or.2015.3768</pub-id><pub-id pub-id-type="pmid">25634589</pub-id><pub-id pub-id-type="pmcid">4440222</pub-id></element-citation></ref>
<ref id="b5-or-38-05-2985"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinghorn</surname><given-names>AD</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Fletcher</surname><given-names>JN</given-names></name><name><surname>Chai</surname><given-names>H</given-names></name></person-group><article-title>The relevance of higher plants in lead compound discovery programs</article-title><source>J Nat Prod</source><volume>74</volume><fpage>1539</fpage><lpage>1555</lpage><year>2011</year><pub-id pub-id-type="doi">10.1021/np200391c</pub-id><pub-id pub-id-type="pmid">21650152</pub-id><pub-id pub-id-type="pmcid">3158731</pub-id></element-citation></ref>
<ref id="b6-or-38-05-2985"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JV</given-names></name><name><surname>Cotter</surname><given-names>TG</given-names></name></person-group><article-title>Cell shrinkage and apoptosis: A role for potassium and sodium ion efflux</article-title><source>Cell Death Differ</source><volume>4</volume><fpage>756</fpage><lpage>770</lpage><year>1997</year><pub-id pub-id-type="doi">10.1038/sj.cdd.4400296</pub-id><pub-id pub-id-type="pmid">16465288</pub-id></element-citation></ref>
<ref id="b7-or-38-05-2985"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>HQ</given-names></name><name><surname>Xue</surname><given-names>SB</given-names></name></person-group><article-title>Apoptosis of HL-60 cells induced by Harringtonine: Membrane blebs, nucleus blebs and chromatin condensation</article-title><source>Shi Yan Sheng Wu Xue Bao</source><volume>29</volume><fpage>221</fpage><lpage>233</lpage><year>1996</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">9639809</pub-id></element-citation></ref>
<ref id="b8-or-38-05-2985"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Kawane</surname><given-names>K</given-names></name><name><surname>Mukae</surname><given-names>N</given-names></name><name><surname>Fukuyama</surname><given-names>H</given-names></name></person-group><article-title>Degradation of chromosomal DNA during apoptosis</article-title><source>Cell Death Differ</source><volume>10</volume><fpage>108</fpage><lpage>116</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/sj.cdd.4401161</pub-id><pub-id pub-id-type="pmid">12655299</pub-id></element-citation></ref>
<ref id="b9-or-38-05-2985"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><article-title>Promoting apoptosis as a strategy for cancer drug discovery</article-title><source>Nat Rev Cancer</source><volume>5</volume><fpage>876</fpage><lpage>885</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/nrc1736</pub-id><pub-id pub-id-type="pmid">16239906</pub-id></element-citation></ref>
<ref id="b10-or-38-05-2985"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>IA</given-names></name><name><surname>Kang</surname><given-names>KR</given-names></name><name><surname>You</surname><given-names>JS</given-names></name><name><surname>Yu</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>GJ</given-names></name><name><surname>Seo</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Biochanin-A antagonizes the interleukin-1&#x03B2;-induced catabolic inflammation through the modulation of NF-&#x03BA;B cellular signaling in primary rat chondrocytes</article-title><source>Biochem Biophys Res Commun</source><volume>477</volume><fpage>723</fpage><lpage>730</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.06.126</pub-id><pub-id pub-id-type="pmid">27363337</pub-id></element-citation></ref>
<ref id="b11-or-38-05-2985"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>NL</given-names></name><name><surname>Piersen</surname><given-names>CE</given-names></name><name><surname>Banuvar</surname><given-names>S</given-names></name><name><surname>Geller</surname><given-names>SE</given-names></name><name><surname>Shulman</surname><given-names>LP</given-names></name><name><surname>Farnsworth</surname><given-names>NR</given-names></name></person-group><article-title>Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: A literature review</article-title><source>Menopause</source><volume>13</volume><fpage>251</fpage><lpage>264</lpage><year>2006</year><pub-id pub-id-type="doi">10.1097/01.gme.0000198297.40269.f7</pub-id><pub-id pub-id-type="pmid">16645539</pub-id></element-citation></ref>
<ref id="b12-or-38-05-2985"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Rimbach</surname><given-names>G</given-names></name><name><surname>Moini</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>ESR and cell culture studies on free radical-scavenging and antioxidant activities of isoflavonoids</article-title><source>Toxicology</source><volume>179</volume><fpage>171</fpage><lpage>180</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0300-483X(02)00241-X</pub-id><pub-id pub-id-type="pmid">12204553</pub-id></element-citation></ref>
<ref id="b13-or-38-05-2985"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Zhai</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Piao</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Biochanin A inhibits lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells</article-title><source>Life Sci</source><volume>136</volume><fpage>36</fpage><lpage>41</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.lfs.2015.06.015</pub-id><pub-id pub-id-type="pmid">26141992</pub-id></element-citation></ref>
<ref id="b14-or-38-05-2985"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>WY</given-names></name><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>WZ</given-names></name><name><surname>Wang</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>HQ</given-names></name><name><surname>Yin</surname><given-names>YY</given-names></name></person-group><article-title>Biochanin A attenuates LPS-induced pro-inflammatory responses and inhibits the activation of the MAPK pathway in BV2 microglial cells</article-title><source>Int J Mol Med</source><volume>35</volume><fpage>391</fpage><lpage>398</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/ijmm.2014.2020</pub-id><pub-id pub-id-type="pmid">25483920</pub-id></element-citation></ref>
<ref id="b15-or-38-05-2985"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puthli</surname><given-names>A</given-names></name><name><surname>Tiwari</surname><given-names>R</given-names></name><name><surname>Mishra</surname><given-names>KP</given-names></name></person-group><article-title>Biochanin A enhances the radiotoxicity in colon tumor cells in vitro</article-title><source>J Environ Pathol Toxicol Oncol</source><volume>32</volume><fpage>189</fpage><lpage>203</lpage><year>2013</year><pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.2013007280</pub-id><pub-id pub-id-type="pmid">24266406</pub-id></element-citation></ref>
<ref id="b16-or-38-05-2985"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szliszka</surname><given-names>E</given-names></name><name><surname>Czuba</surname><given-names>ZP</given-names></name><name><surname>Mertas</surname><given-names>A</given-names></name><name><surname>Paradysz</surname><given-names>A</given-names></name><name><surname>Krol</surname><given-names>W</given-names></name></person-group><article-title>The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis</article-title><source>Urol Oncol</source><volume>31</volume><fpage>331</fpage><lpage>342</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.urolonc.2011.01.019</pub-id><pub-id pub-id-type="pmid">21803611</pub-id></element-citation></ref>
<ref id="b17-or-38-05-2985"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>SJ</given-names></name><name><surname>Chow</surname><given-names>NH</given-names></name><name><surname>Kung</surname><given-names>ML</given-names></name><name><surname>Hung</surname><given-names>TC</given-names></name><name><surname>Chang</surname><given-names>KL</given-names></name></person-group><article-title>Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity</article-title><source>Nutr Cancer</source><volume>45</volume><fpage>113</fpage><lpage>123</lpage><year>2003</year><pub-id pub-id-type="doi">10.1207/S15327914NC4501_13</pub-id><pub-id pub-id-type="pmid">12791511</pub-id></element-citation></ref>
<ref id="b18-or-38-05-2985"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Moon</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Cho</surname><given-names>SS</given-names></name><name><surname>Yoon</surname><given-names>G</given-names></name><name><surname>Im</surname><given-names>HJ</given-names></name><name><surname>You</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway</article-title><source>Oncol Rep</source><volume>31</volume><fpage>755</fpage><lpage>762</lpage><year>2014</year><pub-id pub-id-type="doi">10.3892/or.2013.2929</pub-id><pub-id pub-id-type="pmid">24337492</pub-id></element-citation></ref>
<ref id="b19-or-38-05-2985"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>HM</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells</article-title><source>J Exp Clin Cancer Res</source><volume>35</volume><fpage>149</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s13046-016-0428-6</pub-id><pub-id pub-id-type="pmid">27658586</pub-id><pub-id pub-id-type="pmcid">5034425</pub-id></element-citation></ref>
<ref id="b20-or-38-05-2985"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SM</given-names></name></person-group><article-title>Human papilloma virus in oral cancer</article-title><source>J Korean Assoc Oral Maxillofac Surg</source><volume>42</volume><fpage>327</fpage><lpage>336</lpage><year>2016</year><pub-id pub-id-type="doi">10.5125/jkaoms.2016.42.6.327</pub-id><pub-id pub-id-type="pmid">28053902</pub-id><pub-id pub-id-type="pmcid">5206237</pub-id></element-citation></ref>
<ref id="b21-or-38-05-2985"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>YS</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>BH</given-names></name><name><surname>Kang</surname><given-names>KR</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Oh</surname><given-names>JS</given-names></name><name><surname>You</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Yu</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Berberine-induced anticancer activities in FaDu head and neck squamous cell carcinoma cells</article-title><source>Oncol Rep</source><volume>34</volume><fpage>3025</fpage><lpage>3034</lpage><year>2015</year><pub-id pub-id-type="doi">10.3892/or.2015.4312</pub-id><pub-id pub-id-type="pmid">26503508</pub-id></element-citation></ref>
<ref id="b22-or-38-05-2985"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howren</surname><given-names>MB</given-names></name><name><surname>Christensen</surname><given-names>AJ</given-names></name><name><surname>Karnell</surname><given-names>L Hynds</given-names></name><name><surname>Van Liew</surname><given-names>JR</given-names></name><name><surname>Funk</surname><given-names>GF</given-names></name></person-group><article-title>Influence of pretreatment social support on health-related quality of life in head and neck cancer survivors: Results from a prospective study</article-title><source>Head Neck</source><volume>35</volume><fpage>779</fpage><lpage>787</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/hed.23029</pub-id><pub-id pub-id-type="pmid">22715128</pub-id></element-citation></ref>
<ref id="b23-or-38-05-2985"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafar</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Naseem</surname><given-names>I</given-names></name></person-group><article-title>Cytotoxic activity of soy phytoestrogen coumestrol against human breast cancer MCF-7 cells: Insights into the molecular mechanism</article-title><source>Food Chem Toxicol</source><volume>99</volume><fpage>149</fpage><lpage>161</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.fct.2016.11.034</pub-id><pub-id pub-id-type="pmid">27913286</pub-id></element-citation></ref>
<ref id="b24-or-38-05-2985"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GA</given-names></name><name><surname>Choi</surname><given-names>KC</given-names></name><name><surname>Hwang</surname><given-names>KA</given-names></name></person-group><article-title>Kaempferol, a phytoestrogen, suppressed triclosan-induced epithelial-mesenchymal transition and metastatic-related behaviors of MCF-7 breast cancer cells</article-title><source>Environ Toxicol Pharmacol</source><volume>49</volume><fpage>48</fpage><lpage>57</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.etap.2016.11.016</pub-id><pub-id pub-id-type="pmid">27902959</pub-id></element-citation></ref>
<ref id="b25-or-38-05-2985"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Moon</surname><given-names>SH</given-names></name><name><surname>Nam</surname><given-names>MJ</given-names></name></person-group><article-title>Genistein induces apoptosis by down-regulating thioredoxin-1 in human hepatocellular carcinoma SNU-449 cells</article-title><source>Food Chem Toxicol</source><volume>97</volume><fpage>127</fpage><lpage>134</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.fct.2016.09.003</pub-id><pub-id pub-id-type="pmid">27597132</pub-id></element-citation></ref>
<ref id="b26-or-38-05-2985"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>V</given-names></name><name><surname>Tadinada</surname><given-names>SM</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Sehdev</surname><given-names>V</given-names></name><name><surname>Daniels</surname><given-names>CK</given-names></name><name><surname>Lai</surname><given-names>JC</given-names></name><name><surname>Bhushan</surname><given-names>A</given-names></name></person-group><article-title>Biochanin A reduces pancreatic cancer survival and progression</article-title><source>Anticancer Drugs</source><volume>25</volume><fpage>296</fpage><lpage>302</lpage><year>2014</year><pub-id pub-id-type="doi">10.1097/CAD.0000000000000044</pub-id><pub-id pub-id-type="pmid">24201306</pub-id></element-citation></ref>
<ref id="b27-or-38-05-2985"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruo</surname><given-names>T</given-names></name><name><surname>Naito</surname><given-names>M</given-names></name><name><surname>Tomida</surname><given-names>A</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Mashima</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Haga</surname><given-names>N</given-names></name></person-group><article-title>Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal</article-title><source>Cancer Sci</source><volume>94</volume><fpage>15</fpage><lpage>21</lpage><year>2003</year><pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01345.x</pub-id><pub-id pub-id-type="pmid">12708468</pub-id></element-citation></ref>
<ref id="b28-or-38-05-2985"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Watari</surname><given-names>H</given-names></name><name><surname>AbuAlmaaty</surname><given-names>A</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Sakuragi</surname><given-names>N</given-names></name></person-group><article-title>Apoptosis and molecular targeting therapy in cancer</article-title><source>BioMed Res Int</source><volume>2014</volume><fpage>150845</fpage><year>2014</year><pub-id pub-id-type="doi">10.1155/2014/150845</pub-id><pub-id pub-id-type="pmid">25013758</pub-id><pub-id pub-id-type="pmcid">4075070</pub-id></element-citation></ref>
<ref id="b29-or-38-05-2985"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stec</surname><given-names>R</given-names></name><name><surname>Bodnar</surname><given-names>L</given-names></name><name><surname>Smoter</surname><given-names>M</given-names></name><name><surname>M&#x0105;czewski</surname><given-names>M</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name></person-group><article-title>Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review)</article-title><source>Oncol Lett</source><volume>2</volume><fpage>3</fpage><lpage>11</lpage><year>2011</year><pub-id pub-id-type="pmid">22870121</pub-id></element-citation></ref>
<ref id="b30-or-38-05-2985"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>MJ</given-names></name><name><surname>Chen</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>WE</given-names></name><name><surname>Chien</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>MK</given-names></name><name><surname>Lo</surname><given-names>YS</given-names></name><name><surname>Hsi</surname><given-names>YT</given-names></name><name><surname>Chuang</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name></person-group><article-title>Dehydroandrographolide inhibits oral cancer cell migration and invasion through NF-&#x03BA;B-, AP-1-, and SP-1-modulated matrix metalloproteinase-2 inhibition</article-title><source>Biochem Pharmacol</source><volume>130</volume><fpage>10</fpage><lpage>20</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.bcp.2017.01.011</pub-id><pub-id pub-id-type="pmid">28131848</pub-id></element-citation></ref>
<ref id="b31-or-38-05-2985"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Jacobson</surname><given-names>K</given-names></name><name><surname>Schaller</surname><given-names>MD</given-names></name></person-group><article-title>MAP kinases and cell migration</article-title><source>J Cell Sci</source><volume>117</volume><fpage>4619</fpage><lpage>4628</lpage><year>2004</year><pub-id pub-id-type="doi">10.1242/jcs.01481</pub-id><pub-id pub-id-type="pmid">15371522</pub-id></element-citation></ref>
<ref id="b32-or-38-05-2985"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kole</surname><given-names>L</given-names></name><name><surname>Giri</surname><given-names>B</given-names></name><name><surname>Manna</surname><given-names>SK</given-names></name><name><surname>Pal</surname><given-names>B</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>Biochanin-A, an isoflavon, showed anti-proliferative and anti-inflammatory activities through the inhibition of iNOS expression, p38-MAPK and ATF-2 phosphorylation and blocking NF-&#x03BA;B nuclear translocation</article-title><source>Eur J Pharmacol</source><volume>653</volume><fpage>8</fpage><lpage>15</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2010.11.026</pub-id><pub-id pub-id-type="pmid">21147093</pub-id></element-citation></ref>
<ref id="b33-or-38-05-2985"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>HH</given-names></name><name><surname>Liu</surname><given-names>CJ</given-names></name><name><surname>Shen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>LM</given-names></name><name><surname>Kuo</surname><given-names>WH</given-names></name><name><surname>Lin</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>RJ</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>p38&#x03B1; MAPK mediates 17&#x03B2;-estradiol inhibition of MMP-2 and &#x2212;9 expression and cell migration in human lovo colon cancer cells</article-title><source>J Cell Physiol</source><volume>227</volume><fpage>3648</fpage><lpage>3660</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/jcp.24072</pub-id><pub-id pub-id-type="pmid">22377968</pub-id></element-citation></ref>
<ref id="b34-or-38-05-2985"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromigu&#x00E9;</surname><given-names>O</given-names></name><name><surname>Hamidouche</surname><given-names>Z</given-names></name><name><surname>Marie</surname><given-names>PJ</given-names></name></person-group><article-title>Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion</article-title><source>J Biol Chem</source><volume>283</volume><fpage>30549</fpage><lpage>30556</lpage><year>2008</year><pub-id pub-id-type="doi">10.1074/jbc.M801436200</pub-id><pub-id pub-id-type="pmid">18757369</pub-id><pub-id pub-id-type="pmcid">2662148</pub-id></element-citation></ref>
<ref id="b35-or-38-05-2985"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindhu</surname><given-names>OS</given-names></name><name><surname>Ramadas</surname><given-names>K</given-names></name><name><surname>Sebastian</surname><given-names>P</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name></person-group><article-title>High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma</article-title><source>Head Neck</source><volume>28</volume><fpage>916</fpage><lpage>925</lpage><year>2006</year><pub-id pub-id-type="doi">10.1002/hed.20437</pub-id><pub-id pub-id-type="pmid">16823875</pub-id></element-citation></ref>
<ref id="b36-or-38-05-2985"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Redmond</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>OMalley</surname><given-names>BW</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression</article-title><source>Mol Cell Biol</source><volume>28</volume><fpage>5937</fpage><lpage>5950</lpage><year>2008</year><pub-id pub-id-type="doi">10.1128/MCB.00579-08</pub-id><pub-id pub-id-type="pmid">18644862</pub-id><pub-id pub-id-type="pmcid">2547002</pub-id></element-citation></ref>
<ref id="b37-or-38-05-2985"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>G</given-names></name></person-group><article-title>Major physiological signaling pathways in the regulation of cell proliferation and survival</article-title><source>Handb Exp Pharmacol</source><month>Feb</month><day>24</day><year>2017</year><uri>https://doi.org/10.1007/164_2017_4</uri><pub-id pub-id-type="doi">10.1007/164_2017_4</pub-id></element-citation></ref>
<ref id="b38-or-38-05-2985"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>HX</given-names></name><name><surname>Li</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>ZF</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name></person-group><article-title>Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3&#x03B2;/&#x03B2;-catenin signaling</article-title><source>Oncotarget</source><volume>8</volume><fpage>16972</fpage><lpage>16987</lpage><year>2017</year><pub-id pub-id-type="pmid">28199981</pub-id><pub-id pub-id-type="pmcid">5370015</pub-id></element-citation></ref>
<ref id="b39-or-38-05-2985"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>HS</given-names></name><name><surname>Wang</surname><given-names>YF</given-names></name><name><surname>Tzeng</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>DR</given-names></name><name><surname>Liao</surname><given-names>YF</given-names></name><name><surname>Chiu</surname><given-names>HY</given-names></name><name><surname>Hsieh</surname><given-names>WT</given-names></name></person-group><article-title>Aloe-emodin enhances tamoxifen cytotoxicity by suppressing Ras/ERK and PI3K/mTOR in breast cancer cells</article-title><source>Am J Chin Med</source><volume>45</volume><fpage>337</fpage><lpage>350</lpage><year>2017</year><pub-id pub-id-type="doi">10.1142/S0192415X17500215</pub-id><pub-id pub-id-type="pmid">28231748</pub-id></element-citation></ref>
<ref id="b40-or-38-05-2985"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrami</surname><given-names>A</given-names></name><name><surname>Khazaei</surname><given-names>M</given-names></name><name><surname>Hasanzadeh</surname><given-names>M</given-names></name><name><surname>Sales</surname><given-names>S Shahid</given-names></name><name><surname>Mashhad</surname><given-names>M Joudi</given-names></name><name><surname>Farazestanian</surname><given-names>M</given-names></name><name><surname>Sadeghnia</surname><given-names>HR</given-names></name><name><surname>Rezayi</surname><given-names>M</given-names></name><name><surname>Maftouh</surname><given-names>M</given-names></name><name><surname>Hassanian</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer: Rational and progress</article-title><source>J Cell Biochem</source><month>Feb</month><day>23</day><year>2017</year><comment>(Epub ahead of print). doi: 10.1002/jcb.25950</comment><pub-id pub-id-type="doi">10.1002/jcb.26136</pub-id></element-citation></ref>
<ref id="b41-or-38-05-2985"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lux</surname><given-names>MP</given-names></name><name><surname>Fasching</surname><given-names>PA</given-names></name><name><surname>Schrauder</surname><given-names>MG</given-names></name><name><surname>Hein</surname><given-names>A</given-names></name><name><surname>Jud</surname><given-names>SM</given-names></name><name><surname>Rauh</surname><given-names>C</given-names></name><name><surname>Beckmann</surname><given-names>MW</given-names></name></person-group><article-title>The PI3K Pathway: Background and treatment approaches</article-title><source>Breast Care (Basel)</source><volume>11</volume><fpage>398</fpage><lpage>404</lpage><year>2016</year><pub-id pub-id-type="doi">10.1159/000453133</pub-id><pub-id pub-id-type="pmid">28228706</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-38-05-2985" position="float">
<label>Figure 1.</label>
<caption><p>Biochanin-A induces cell death through the increase of cytotoxicity in FaDu cells. (A) Biochanin-A decreases the viability of FaDu cells in a dose- and time-dependent manner. FaDu cells were treated with different doses of Biochanin-A (0, 25, 50 and 100 &#x00B5;M) for 24 and 48 h. Under the indicated treatment conditions, cell viability was measured using an MTT assay. The data represent the results of three independent experiments and are expressed as the mean &#x00B1; standard deviation (SD; &#x002A;P&#x003C;0.05 and &#x002A;&#x002A;P&#x003C;0.01 compared to the control). (B) Biochanin-A induces the death of FaDu cells. FaDu cells cultured at a density of 0.2&#x00D7;10<sup>5</sup> cells/ml in 8-well chamber slide were stimulated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Live cells were stained with green calcein-AM and dead cells were stained with ethidium homodimer-1 (red) and then examined and photographed using fluorescence microscopy (Eclipse TE200; Nikon Instruments).</p></caption>
<graphic xlink:href="OR-38-05-2985-g00.tif"/>
</fig>
<fig id="f2-or-38-05-2985" position="float">
<label>Figure 2.</label>
<caption><p>Biochanin-A-induced FaDu cell death is mediated by apoptosis. (A) Biochanin-A increases FaDu cells with condensed nucleus in a dose-dependent manner. Detection of apoptotic cells was accomplished by fluorescently staining DNA to examine chromosomal condensation. FaDu cells cultured at a density of 1&#x00D7;10<sup>5</sup> cells/ml were treated with 0, 25 and 50 &#x00B5;M biochanin-A and incubated for 24 h. Cells were stained with 4&#x2013;6-diamidino-2-phenylindole (DAPI) and then examined and photographed using fluorescence microscopy. (B) Increased apoptotic population in FaDu cells treated with biochanin-A. Flow cytometric analysis was performed on cells co-stained with Annexin V-FITC and propidium iodide (PI) (Cell Signaling Technology) to detect apoptosis. After 5&#x00D7;10<sup>5</sup> cells/ml of FaDu cells were plated into a 6-well plate. After 24 h, the cells were treated with 50 &#x00B5;M biochanin-A. Both floating and attached cells were then collected, washed twice with ice-cold phosphate-buffered saline, and resuspended in 500 &#x00B5;l of 1X binding buffer. Annexin V-FITC and PI were added to the cells for 15 min at 37&#x00B0;C in the dark. The population of Annexin V-positive cells and the cell cycle phase were analyzed using a BD CellQuest<sup>&#x00AE;</sup> version 3.3 instrument (Becton-Dickinson) and WinMDI version 2.9 software (The Scripps Research Institute).</p></caption>
<graphic xlink:href="OR-38-05-2985-g01.tif"/>
</fig>
<fig id="f3-or-38-05-2985" position="float">
<label>Figure 3.</label>
<caption><p>Biochanin-A-induced apoptosis is mediated by extrinsic and intrinsic apoptotic pathways. FaDu cells cultured at a density of 1&#x00D7;10<sup>5</sup> cells/ml in 6-well plates were stimulated with 25 and 50 &#x00B5;M biochanin-A for 24 h. The activation of caspase-3 and PARP via biochanin-A induced extrinsic death receptor-dependent and intrinsic mitochondrial-dependent apoptosis signaling pathways. Biochanin-A -induced apoptosis of FaDu cells is dependent on caspase activation.</p></caption>
<graphic xlink:href="OR-38-05-2985-g02.tif"/>
</fig>
<fig id="f4-or-38-05-2985" position="float">
<label>Figure 4.</label>
<caption><p>Biochanin-A suppresses the migration and proliferation of FaDu cells through downregulation and inactivation of matrix metalloproteinase (MMP)-2 and &#x2212;9. (A) Wound healing migration is attenuated in FaDu cells treated with biochanin-A. FaDu cells were treated with 25 &#x00B5;M biochanin-A for 48 and 72 h. Wound widths were imaged using reverse microscopy (Eclipse TE2000; Nikon Instruments). (B) Biochanin-A suppresses the proliferation of FaDu cells. To perform a colony formation assay, FaDu cells were treated with 25 &#x00B5;M biochanin-A for 24 h and then were incubated in the culture media without biochanin-A for 5 days. Thereafter, formed colonies were stained by crystal violet and were counted. (C and D) The expressions and activities of MMP-2 and MMP-9 decreased in FaDu cells treated with biochanin-A in a dose-dependent manner. FaDu cells were stimulated with 25 and 50 &#x00B5;M biochanin-A for 24 h. Thereafter, (C) immunoblotting and (D) gelatin zymography were performed to verify the expression and activity of MMP-2 and MMP-9 in the conditioned media of FaDu cells treated with biochanin-A, respectively.</p></caption>
<graphic xlink:href="OR-38-05-2985-g03.tif"/>
</fig>
<fig id="f5-or-38-05-2985" position="float">
<label>Figure 5.</label>
<caption><p>Biochanin-A suppresses the migration and proliferation of FaDu cells through the inhibition of p38 MAPK, NF-&#x03BA;B and Akt phosphorylation. FaDu cells cultured at a density of 1&#x00D7;10<sup>5</sup> cells/ml in 6-well plates were stimulated with 50 &#x00B5;M biochanin-A for 30 and 60 min. Thereafter, FaDu cells were harvested and lysed using cell lysis buffer containing the phosphatase inhibitors. Immunoblotting was performed to verify the alterations of ERK1/2, p38, NF-&#x03BA;B and Akt. The immunoreactive bands were visualized using the ECL system and were exposed on radiographic film.</p></caption>
<graphic xlink:href="OR-38-05-2985-g04.tif"/>
</fig>
</floats-group>
</article>